• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: KANEKA CORPORATION LIPOSORBER LA015 SYSTEM; LDL APHERESIS SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

KANEKA CORPORATION LIPOSORBER LA015 SYSTEM; LDL APHERESIS SYSTEM Back to Search Results
Model Number LA-15
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Cardiopulmonary Arrest (1765); Death (1802); Disseminated Intravascular Coagulation (DIC) (1813); Edema (1820); Embolism (1829); Hemorrhage/Bleeding (1888); Hemorrhage, Intraventricular (1892); Low Blood Pressure/ Hypotension (1914); Respiratory Distress (2045); Loss of consciousness (2418)
Event Date 02/24/2014
Event Type  Death  
Event Description
Te ldl-apheresis (ldl-a) with liposorber la-15 system was applied to the patient (pt) for the treatment of his arterio sclerosis obliterans (aso).He has developed cholesterol crystal embolization (cce) after receiving a percutaneous coronary intervention (pci).He rec'd the first ldl-a on (b)(6) (10 days ago), and it was his second treatment with the ldl-a.He also developed disseminated intravascular coagulation syndrome (dic) developed, and a gastrointestinal bleeding was observed on the day of the ldl-a.On the day of the event, he rec'd first a continuous hemodiafiltration (chdf) followed by the ldl-a in icu.At the start of the ldl-a procedure, he had already a difficulty to breath normally with mandibular-breathing, edema of the whole body, lower level of consciousness, and the blood pressure (bp) was 90mmhg.His bp further dropped during the ldl-a, and he developed a very severe hypotension to become unconscious, and cardiopulmonary arrest at around one (1) hour after starting the procedure.The ldl-a was immediately terminated, cardiac compression was performed, adrenalin was given by intracardiac injection, and cardiac compression was continued, but the patient died.The time course of the ldl-a on that day was as follows: 11:15 (am), the ldl-a was initiated with the operating conditions of the blood flow rate (qb) with 70ml/min and a plasma filtration ratio (qf) of 20% (14ml/min).The patient's bp was 90mmhg, 11:40, his bp dropped to 60mmhg from 70mmhg and qb was reduced to 60ml/min., at around 500ml of processing plasma volume, 11:50, no sign of his bp's going up was seen, 12:00, qb was further reduced to 50ml/min., at around 800ml of processing plasma volume, 12:10, his bp dropped to 30-40mmhg and the operating nurse called the doctor for the termination of the treatment.At 12:15, the nurse stopped the pumps of the apheresis machine and intended to return the blood and the plasma to the patient; however, the patient's condition suddenly deteriorated to become unconscious with cardiac arrest and performed cardiac compression.Adrenaline was given by intracardiac injection and cardiac compression was continued; however, patient died.
 
Manufacturer Narrative
According to the physician in charge, the patient had developed dic, gastrointestinal bleeding necessitated with blood transfusion, and his physical status was very poor with mandibular breathing, lower bp with lower consciousness level when the ldl-a was started after a chdf.The physician in charge commented that the patient's death was not attributable to the ldl-a itself taking into account the circumstances of the patient's physical conditions although it could not completely be excluded since the hypotension resulted finally in the patient's death occurred during the ldl-a procedure.We believe that the patient's physical condition on the day of the event was too poor and intolerable to the ldl-a procedure, and accordingly, the patient's death is attributable neither to the device failure nor the ldl-a itself with the device.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LIPOSORBER LA015 SYSTEM
Type of Device
LDL APHERESIS SYSTEM
Manufacturer (Section D)
KANEKA CORPORATION
osaka
JA 
Manufacturer (Section G)
KANEKA CORPORATION
2-3-18 nakanoshima, kita-ku
osaka 530- 8288
JA   530-8288
Manufacturer Contact
masaharu inoue
546 fifth avenue 21st floor
new york, NY 10036
8005263522
MDR Report Key3678702
MDR Text Key4299983
Report Number9614654-2014-00004
Device Sequence Number1
Product Code MMY
Combination Product (y/n)N
Reporter Country CodeJA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 03/04/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/13/2014
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberLA-15
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
MA-03 APHERESIS MACHINE (NIKKISO CO., LTD); PLASMA SEPARATOR; NK-M3R TUBING SET (NIKKISO CO., LTD); SULFUX FP-08 (ASAHI-KASEI MEDICAL CO., LTD)
Patient Outcome(s) Death;
Patient Age86 YR
-
-